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The role of migraine as an independent risk factor for cardiovascular events has been debated for several years,
while it is more established for ischemic stroke. Recently, new studies have examined the likelihood of migraine to
determine cardiovascular events, supporting the hypothesis of a predominant role in patients with migraine with
aura, the risk including both sexes. In the literature, multiple pathophysiological mechanisms are described to
explain this association, and are here discussed. Furthermore, the emerging evidence that a higher headache
frequency and long-term migraine may worsen the cardio-metabolic profile in migraineurs (e.g. with a higher
Framingham risk score and risk of developing atherosclerosis, insulin resistance and metabolic syndrome) makes it
increasingly necessary to reduce the number and severity of attacks, not only to alleviate the painful symptoms, but
also to improve the prognosis in these patients.
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Although mortality from cardiovascular disease (CVD)
has considerably decreased in recent decades, mainly
due to a better primary prevention (e.g. smoking cessa-
tion, diet and lifestyle changes), it still remains the lead-
ing cause of premature death in developed countries [1],
constituting the underlying cause in 36.3% of cases in
the United States [2].
Risk factors can be traditionally classified as non-
modifiable (age and gender) and modifiable (e.g. history
of hypertension, diabetes, smoking, lack of a regular diet
and physical activity) [1-3].
In the case–control INTERHEART study, increased
ApoB/ApoA1 ratio (OR 3.25 for top vs lowest quintile),
smoking (2.87 for current vs never), history of diabetes
(2.37), hypertension (1.91), abdominal obesity (1.12
for top vs lowest tertile and 1.62 for middle vs
lowest tertile), psychosocial factors (2.67), lack of daily* Correspondence: mag@unich.it
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in any medium, provided the original work is pconsumption of fruit and vegetables (0.70), regular alco-
hol consumption (0.91) and lack of regular physical
activity (0.86) have been significantly associated with
myocardial infarction in the United States (p < 0.0001 for
all risk factors and p = 0.03 for alcohol) [3]. The role of
migraine as a cardiovascular risk factor has been debated
for years, while it seemed to be more established for
ischemic stroke. Recent studies have therefore examined
its likelihood to determine cardiovascular events, and
these are discussed below. Furthermore, new data are
available about the role of white matter hyperintensities
(WMHs) in migraine patients [4].Review
Migraine as an independent risk factor for vascular
events: what’s new?
Recent evidence from the literature
Several studies have investigated the complex relation-
ship between migraine and the risk of cardio- and cere-
brovascular events, a possible link having already been
hypothesized twenty years ago [5]. In a large prospective
cohort study which enrolled, from the Women’s Health
Study, 27,840 US migraineur women aged 45 years orOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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et al. reported 580 major CVD events during a mean
follow-up of 10 years. Women who reported active
migraine with aura (MA) had multivariable-adjusted
hazard ratios of 2.33 (95% CI, 1.21-4.51; P = .01) for is-
chemic CVD death, 2.15 (95% confidence interval [CI],
1.58-2.92; P < .001) for major CVD, 2.08 (95% CI, 1.30-
3.31; P = .002) for myocardial infarction, 1.91 (95% CI,
1.17-3.10; P = .01) for ischemic stroke, 1.74 (95% CI,
1.23-2.46; P = .002) for coronary revascularization, and
1.71 (95% CI, 1.16-2.53; P = .007) for angina, compared
with women with no migraine history. Migraine without
aura (MO) was not associated with an increased risk of
any CVD event [6]. An increased risk of ischemic stroke
had already been documented previously in different
case control studies [7-9] and, subsequently, in a system-
atic review and meta-analysis of 14 observational studies
published between 1966 and June 2004 (RR 2.16, 95% CI
1.89 to 2.48), which also showed an increased risk of
these events both in patients with (RR 2.27, CI 1.61 to
3.19) and without aura (RR 1.83, CI 1.06 to 3.15), as well
as in those taking oral contraceptives (RR 8.72, 5.05 to
15.05) [10].
Later, Schürks et al. confirmed a twofold increased
hazard of ischaemic stroke in migraine patients, particu-
larly women, affected with MA, aged < 45 years, smokers
and with a history of the use of oral contraceptives. In
contrast with previous data, the authors did not find an
overall association between any migraine and myocardial
infarction, death due to cardiovascular disease [11] or, in
another work, mortality from all causes, CVD, or coron-
ary heart disease (CHD). They documented, however, a
moderate to high heterogeneity among included studies
[12]. In men, migraine seems to have a major role in
cardiovascular diseases, compared with nonmigraineurs;
indeed, in a prospective cohort study of 20,084 men
aged 40 to 84 years free of CVD at the start, who partici-
pated in the Physicians’ Health Study, Kurth et al. found,
among 1449 men reporting migraine, 2236 major CVD
events during a mean follow-up of 15.7 years, with
multivariable-adjusted hazard ratios (95% confidence
intervals) of 1.42 (1.15-1.77; P < .001) for myocardial in-
farction, 1.24 (1.06-1.46; P = .008) for major CVD, 1.12
(0.84-1.50; P = .43) for ischemic stroke, 1.15 (0.99-1.33;
P = .068) for angina, 1.07 (0.80-1.43; P = .65) for ischemic
cardiovascular death, and 1.05 (0.89-1.24; P = .54) for
coronary revascularization, compared to patients
without migraine. Therefore, this study highlights
the important role of migraine as a cardiovascular
risk factor in men, in particular for myocardial in-
farction. The main limit of this trial was the unavail-
ability of data about aura; furthermore, male gender
constitutes, per se, a risk factor for cardiovascular
disease [13].Recently, Gudmundsson et al. have again raised the
hypothesis about migraine as an independent CV risk
factor in both sexes, reporting, in a population based
cohort study among 18,725 men and women born in the
period 1907–35, an increased risk of all-cause mortality
(adjusted - for sex and multivariables- hazard ratio 1.21,
95% CI 1.12 to 1.30), mortality from cardiovascular
disease (1.27, 1.13 to 1.43), mortality from coronary
heart disease (1.28, 1.11 to 1.49) and stroke (1.40, 1.10 to
1.78) in patients with migraine with aura compared with
headache-free controls, while those with migraine
without aura and non-migraine headache had no
increased risk. The authors also showed that migraineur
women had an increased risk of mortality from non-
cardiovascular disease (1.19, 1.06 to 1.35) [14]. A post-
hoc subgroup analysis of the Women’s Health Study,
which randomized 100 mg aspirin on alternate days in
primary prevention of CVD among 39,876 women
aged ≥ 45 years, showed that aspirin reduced the risk of
ischaemic stroke (RR, 0.76, 95% CI 0.63-0.93) but not of
other CVD. Conversely, female patients with migraine
with aura, who were assigned to aspirin, had an increased
risk of myocardial infarction (RR 3.72, 95% CI 1.39-9.95);
this was evident only for nonsmokers or those affected
with hypertension (p < 0.01) [15]. Other authors have
instead shown that migraine patients tend to have a
significantly enhanced risk of venous thromboembolism
(18.9% vs 7.6% in non-migraineurs, age/sex-adjusted
p = 0.031) [16].
Common mechanisms for different diseases?
A putative link between migraine and the risk of cardio-
vascular events can be supported by the detection of
higher concentrations of some serum markers in migrai-
neurs compared to controls; pro-brain natriuretic pep-
tide (pro-BNP) has been found to be elevated compared
with healthy subjects (27.0 ± 28.0 versus 13.2 ± 8.6, p =
0.006), suggesting a preclinical cardiac involvement
in these patients [17]. Serum from migraineurs, com-
pared to controls, has also shown a condition of pro-
inflammatory state: Uzar et al. have indeed documented
the presence of higher levels of IL-1beta and IL-6 com-
pared to controls (for IL-1beta; 5.73 ± 1.44 vs. 4.90 ±
1.40 pg/mL, respectively, p = 0.006; for IL-6; 3.1 ± 1.44
vs. 2.40 ± 0.22 pg/mL, respectively, p = 0.007) and lower
values of IL-10 (3.38 ± 2.93 pg/mL) than healthy sub-
jects (6.76 ± 1.48 pg/mL) (p = 0.007) [17]. Furthermore,
in migraine patients, particularly those with aura, there
was a significant reduction of the number and function
of circulating endothelial progenitor cells [18] (EPCs,
which appear to be involved in repair and angiogenesis
of ischemic tissues [19]), compared to controls and
patients with tension type headache (8.6 ± 10.1 in MA
versus 20.4 ± 22.2 in MO, p = 0.001; 47.8 ± 24.3 in TTH
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migratory capacity and increased cellular senescence in
migraineurs, suggested that EPCs are another underlying
link between migraine and cardiovascular risk [18]. The
presence of altered endothelial function in migraineurs
has recently been confirmed by Rodríguez-Osorio et al.,
who analyzed flow-mediated dilation (FMD) in the dom-
inant brachial artery, calcitonin gene-related peptide
(CGRP), and vascular endothelial growth factor (VEGF)
levels by ELISA, nitric oxide stable metabolites (NOx)
by high-performance liquid chromatography, and EPCs
in peripheral blood samples of 47 patients with a diagno-
sis of episodic migraine performed according to the
International Headache Society (IHS) 2004 criteria, and
of 23 control subjects, obtained during interictal periods
and migraine attacks. Compared to controls, migraineurs
showed reduced levels of EPCs (9.4 ± 5.0 vs 17.9 ± 6.0;
p < 0.0001), higher values of NOx (1225.2 ± 466.1 vs
671.9 ± 358.6 μM), VEGF (473.4 ± 398.7 vs 72.6 ± 56.6
pg/mL), and CGRP (164.2 ± 139.1 vs 37.1 ± 38.5 pg/mL)
(p < 0.05); higher levels of these markers were reported
during attacks. An interesting result was that EPC
counts decreased as migraine progressed in time [20].
An adverse cardiovascular profile in patients with mi-
graine may also be explained by the detection of a con-
dition of oxidative stress, in terms of both an increase in
oxidising substances and antioxidant mechanisms [21].
Malondialdehyde (MDA) levels and erythrocyte super-
oxide dismutase (SOD) activity were, indeed, signifi-
cantly higher in migraineurs than in controls, as shown
by Tuncel et al. The SOD activity was significantly
higher in the MA subgroup as compared to MO [22].
The levels of 4-hydroxy-2-nonenal (HNE), increased in
female patients compared to controls (OR for migraine
of 4.55), were significantly correlated with the nitric
oxide pathway, insulin- and lipid-metabolism [23]. Fur-
thermore, Gupta et al. assessed the oxidative stress in
migraineurs and TTH subjects by collecting a venous
blood sample from the antecubital vein at least 3 days
after the last headache attack. They found higher values
of malondialdehyde (MDA) and ferric reducing activity
of plasma (FRAP) in migraine patients than in the
subjects with TTH and controls (P < 0.001). Compared
to MO, FRAP levels were significantly higher in
patients with mixed migraine (MA and MO, P =
0.01) [24]. Migraineurs have also been shown to
present higher concentrations of nitric oxide (NO,
35.6 ± 7.7, 31.0 ± 6.2 μmol/L, respectively, p = 0.005)
and asymmetric dimethylarginine (ADMA, 0.409 ±
0.028, 0.381 ± 0.044 μmol/L, respectively, p = 0.001)
in comparison with controls. During the crises, NO
and ADMA concentrations were significantly higher
in migraine patients compared to healthy subjects
(p = 0.015 and p = 0.014, respectively) [25].As far as NO and ADMA are concerned, migraine
patients compared to controls showed higher levels of
platelet peroxynitrite (ONOO-), a reactive oxidant
derived from superoxide anion and NO (P < 0.001); it
has been suggested that this could be related to changes
in fluidity and activity of platelet membrane [26]. Lastly,
it is interesting to note that N-acetyl-aspartate (NAA), a
serum biomarker of neuronal integrity synthesized in
neural mitochondria [27], has recently been found to
be significantly decreased in migraineurs (0065 ±
0019 mol/L, with lower levels in those with aura), as
compared with both tension-type headache patients
(0078 ± 0016 mol/L, p = 0.002) and controls (0085 ±
0013 mol/L, p <0.0001) [28]. Reduced levels of NAA
could be associated with an increased risk of stroke and
migraine progression [27]. Figure 1 shows the mechan-
isms which may increase the risk of vascular events in
migraine patients.
Cardiovascular risk profile in patients with migraine and
interactions between risk factors
The Framingham risk score
In all asymptomatic adults without a clinical history of
CHD, the risk of cardiovascular events should be
assessed by global risk scores, such as the Framingham
Risk Score in the American population, which combines
multiple traditional cardiovascular risk factors (such as
age, sex, total cholesterol, HDL cholesterol, smoking,
systolic blood pressure, antihypertensive medications)
into a single quantitative estimate of risk which can be
used to target preventive interventions [29,30]. Several
trials have evaluated the Framingham risk score in the
population of migraineurs; the recent cross-sectional
population-based HUNT study enrolled 48,713 subjects
(age ≥ 20 years) and in 44,098 (90.5%) of these assessed
parameters such as blood pressure (BP), body mass
index (BMI), serum total and high-density lipoprotein
cholesterol to calculate the Framingham 10-year risk
score for coronary death and myocardial infarction. The
authors found an unfavourable cardiovascular risk pro-
file, established by an elevated Framingham risk score,
both in migraine with (OR 1.54, 95% CI 1.21-1.95) and
without aura (OR 1.17, 95% CI 1.04-1.32) and in non-
migrainous headache (OR 1.17, 95% CI 1.10-1.26). As
shown above, the risk was more pronounced in patients
with migraine with aura, confirming its major link with
CV diseases. A very interesting result was that the
Framingham risk score consistently increased with a
higher headache frequency. For non-migrainous head-
ache and migraine without aura, the increased risk was
accounted for by lifestyle factors such as low physical
activity, smoking and a high BMI; conversely, these
factors did not completely explain the elevated risk in
the patients with migraine with aura, suggesting other
Figure 1 Putative mechanisms which may increase the risk of vascular events in patients with migraine. EPCs Endothelial Progenitor
Cells; NSAIDs Non-steroidal anti-inflammatory drugs.
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in other headache types [31].
Metabolic syndrome and its components
The complexity of the relationship between migraine
and the risk of cardio and cerebrovascular diseases may
be partly explained by the detection of a higher preva-
lence of multiple risk factors in these patients than con-
trols; this may suggest an interaction between them,
enhancing the CV risk profile in migraineurs. These
patients have indeed demonstrated a higher prevalence
of metabolic syndrome than the general population
[32,33], with a correlation with age, gender, number of
triggers, years of headache and duration of migraine
attacks [33].
From the Genetic Epidemiology of Migraine (GEM)
population-based study conducted in the Netherlands,
620 patients with migraine were identified among 5,755
enrolled participants. Compared to controls, they were
more likely to be smokers (OR = 1.43 [1.1 to 1.8]) and
have a parental history of early myocardial infarction,
and they were less likely to be alcohol consumers (OR =
0.58 [0.5 to 0.7]). Furthermore, migraine with aura
patients were more likely to have elevated blood pres-
sure (systolic BP > 140 mm Hg or diastolic BP > 90 mm
Hg [OR = 1.76 (1.04 to 3.0)]), a worse cholesterol profile(TC > or = 240 mg/dL [OR = 1.43 (0.97 to 2.1)], TC:HDL
ratio > 5.0 [OR = 1.64 (1.1 to 2.4)]), and an earlier onset
of CHD or stroke (OR = 3.96 [1.1 to 14.3]), with doubled
odds of having an elevated Framingham risk, resulting
in a higher CV risk profile than patients without
migraine [34].
Lipidic profile
According to these data, the recent population-based
study by Bigal et al. found that migraineurs, compared
to controls, were more likely to have a diagnosis of
hypercholesterolemia (32.7% vs 25.6%, OR 1.4, 95% CI
1.3-1.5), but also diabetes (12.6% vs 9.4%, OR 1.4, 95%
CI 1.2-1.6) and hypertension (33.1% vs 27.5%, OR 1.4,
95% CI 1.3-1.6). The risk was highest in patients with
migraine with aura, but remained increased in those
without aura, with significant higher Framingham scores
in both than in controls. After adjustments for CVD risk
factors, gender, age, disability and treatment, migraine
remained significantly associated with myocardial in-
farction (OR 2.2, 95% CI 1.7-2.8), stroke (OR 1.5,
95% CI 1.2-2.1), and claudication (OR 2.69, 95% CI
1.98-3.23) [35].
A significant elevation of total cholesterol and trigly-
cerides was also found among migraine with aura
patients enrolled in the cross-sectional Epidemiology of
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was indeed 4.67 (0.99-21.97) for the 2nd tertile and 5.97
(1.29-27.61) for the 3rd tertile of total cholesterol and
OR of 4.42 (1.32-14.77) for the 3rd tertile of triglycer-
ides. A significant association between increased bio-
marker levels and any other headache group was not
found [36].
Obesity
Obesity has been found to be another important cardio-
vascular risk factor associated with migraine, especially
with a new onset chronic daily headache (CDH), higher
frequency and intensity of migraine crises [37-39]. With
respect to BMI, Bigal et al. have indeed shown an in-
crease in the proportion of subjects with severe head-
ache pain and a doubling of cases in the morbidly obese
group (BMI > or = 35 kg/m(2)) compared to the normally
weighted group (BMI 18.5 to 24.9 kg/m(2); OR = 1.9). A
greater BMI was, indeed, directly correlated with an ele-
vated number of headache crises [4.4% of cases with 10
to 15 headache days per month in the normally weighted
group, 5.8% in the overweight (OR = 1.3), 13.6% in the
obese (OR = 2.9), and 20.7% in the morbidly obese group
(OR = 5.7)] [38].
Furthermore, for a BMI > or = 35 kg/m(2), an OR of
daily migraine of 3.11 (1.12, 8.67) has been shown in
women and, among those with an active form, a higher
risk was present of phonophobia and photophobia
but not of migraine with aura, which was instead
decreased [39].
Hyperinsulinemia and glucose tolerance
In addition to the risk factors discussed above, there is
growing evidence that alterations of the glucose metab-
olism may be related to migraine and involved in its
pathogenesis. In a study which enrolled 84 patients with
migraine (73 F, 11 M), 25 patients with non-migraine
headache (20 F, 5 M), and 26 healthy subjects (24 F,
2 M), some authors showed the presence of higher
levels of insulin in migraine than in other headaches
(P < .0001) and controls (P < .0001), and higher levels of
blood glucose in headache patients, with a greater differ-
ence between migraine and healthy subjects (P < .0001)
than between other headaches and controls (P < .05). In
this study, therefore, unlike glucose levels, hyperinsuline-
mia appeared to be specific for migraine patients [40].
Moreover, a higher prevalence of insulin resistance has
been found [33,41], as well as a correlation of this with
the duration of migraine attacks [33]. Similar data were
obtained by Gruber et al., who enrolled one hundred
and twenty non-obese subjects, including 48 migraineurs
and 72 healthy volunteers; they found high levels of
insulin in migraine patients and also showed a link be-
tween migraine-related hyperinsulinemia and increasedNO stress [42]. Correlated with high levels of insulin,
leptin and GLP-2 levels were also found to be increased
in 84 non-obese female patients, revealing ORs of 3.79
and 4.26 for migraine, respectively, when comparing the
lowest with the highest quartile of the test variable in
the complete study cohort by logistic regression ana-
lysis [43].
Migraine and subclinical organ damage
Microvascular abnormalities
In view of the increased susceptibility of patients with
migraine to vascular events, it would be useful to inves-
tigate the presence of subclinical organ damage, which
may further increase the cardiovascular risk in migrai-
neurs. Carotid intima-media thickness (CIMT) is in-
creasingly used as a surrogate marker for atherosclerosis
[44], and has proved to be higher in patients with
migraine than in healthy controls. After matching for
gender, age, BMI, blood pressure, and cholesterol, the
real-time gray-scale ultrasound examination of the left
common carotid arteries (CCA) of 30 patients with a
diagnosis of episodic migraine, carried out according to
the IHS criteria, and of 60 healthy controls aged between
20 and 40 years, showed the presence of significantly
higher IMT values in migraineurs, with a mean CCA-
IMT of 0.493 ± 0.074 mm in migraine patients and of
0.409 ± 0.053 mm in controls (P < 0.001). The authors of
the study concluded that the risk of arteriopathy
increased with the repeating of the migraine attacks,
supporting the role of the severity of attacks (in terms of
number and duration) in the development of athero-
sclerosis [45]. In migraineurs, CIMT was also correlated
with systolic blood pressure (SBP, p < .01), total choles-
terol (P < .01), triglycerides (P < .001), glucose (P < .001),
insulin (P < .01) and BMI (P < .05). The artery flow-
mediated dilatation (FMD) in response to hyperemia
was instead inversely correlated with these parameters,
in particular SBP (P < .001), DBP (P < .01), glucose
(P < .001) and insulin levels (P < .01). Plasma endothelin
(ET)-1, a marker of endothelial injury and atheroscler-
osis released by vascular smooth muscle cells, was
increased in these patients and correlated with the dur-
ation of illness, IMT, FMD% and other clinical-
laboratory parameters (SBP, DBP, insulin and glucose
levels) [46].
A sub-study of the Atherosclerosis Risk in Communi-
ties Study has also found that patients with headache,
compared to those without a history of it, were more
likely to present retinopathy (OR = 1.49, 95% CI = 1.05
to 2.12 for migraine without aura; OR = 1.38, 95% CI =
0.96 to 1.99 for migraine/other headaches with aura; and
OR = 1.28, 95% CI = 0.99 to 1.65 for other headaches),
with a stronger association in the subset of patients
without a history of hypertension or diabetes (OR = 1.79,
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aura; and OR = 1.74, 95% CI = 1.11 to 2.71 for migraine
without aura). The most frequently reported sign of
retinopathy consisted of a reduction of mean arteriolar
and venular calibers with respect to controls [47].
The role of white matter hyperintensities
Definition, pathophysiology and clinical relevance in
headache-free patients
White matter hyperintensities can be defined as small,
non-specific, multiple lesions of the brain, usually
located in the periventricular or deep white matter. They
do not create mass effect on the surrounding paren-
chyma and mainly appear as hyperintense on T2-
weighted and FLAIR images [4]. Microscopically, they
are characterized by the presence of local loss of myelin,
axons and oligodendroglial cells and by a mild reactive
astrocytic gliosis [48]. Many theories have been proposed
to explain their formation, the most accepted being that
white matter hyperintensities are the result of an incom-
plete process of ischemia due to arteriolosclerosis of
small vessels in the brain. They are indeed mainly
related to the aging process and multiple vascular risk
factors, such as hypertension, elevated BMI, hyperchol-
esterolemia and diabetes [48-52]. Other proposed theor-
ies are blood–brain barrier dysfunction due to small
vessel alterations, and consequent chronic diffusion of
macromolecules and fluids in the white matter; oxidative
stress, endothelial dysfunction and dysfunction of
mechanisms of vascular regulation [48]. A large amount
of data have documented the clinical relevance of these
lesions in non-headache people; WMHs have indeed
been associated with cognitive impairment (both in
terms of global cognition, executive function, mental
and processing speed), long-term cognitive decline, gait
disturbance and falls, stroke, death, depression and urin-
ary incontinence [48,53-60].
WMHs in migraine patients: recent evidence
Several studies have documented a higher prevalence of
these lesions in migraineurs (both with and without
aura) than in control subjects, after adjustment for risk
factors [61-63].
In a study which randomly selected 134 patients with
MO, 161 with MA, and 140 controls from the GEM
study, after adjustment for migraine type, attack fre-
quency, age at onset and treatment status, Kruit et al.
found the presence of WMHs in 1 of 140 controls
(0.7%) and in 13 of 295 patients with migraine (4.4%;
P = 0.04), slightly more in MA (8 of 161; 5.0%) than in
MO (5 of 134; 3.7%) [64]. According to previous data
[63], they found an increased prevalence of periventricu-
lar and subcortical white matter lesions (PVWMLs and
DWMLs, respectively), but not of cerebellar infarcts,unlike their earlier study. In the majority of cases (86%),
the lesions were located in the pons (pontine hyperin-
tense lesions [PHLs]) [64]. The recent Cerebral Abnor-
malities in Migraine, an Epidemiological Risk Analysis
(CAMERA) study, which randomly selected 295 patients
with migraine and 140 controls from a previously diag-
nosed population-based sample (n = 6039), showed a
higher prevalence of subclinical infarcts in the posterior
circulation, most pronounced for patients who were
migraineurs with aura [OR 13.7; 95% CI 1.7, 112], and of
brainstem hyperintense lesions (4.4% vs. 0.7%, P = 0.04).
Women with migraine had an independent increased
risk of WMLs (OR 2.1; 95% CI 1.0, 4.1). The authors
found other interesting results, such as a higher lifetime
prevalence of syncope and orthostatic insufficiency in
migraine patients and, in those aged < 50 years, the
presence of increased iron accumulations in red
nucleus (P = 0.03) and basal ganglia such as globus
pallidus (P = 0.03) and putamen (P = 0.02) [65].Pathophysiology and clinical relevance of WMHs in
migraine patients
The reason for the higher prevalence of WMHs in
migraineurs is still debated: the subclinical ischemia the-
ory is the most attractive. The higher prevalence of these
phenomena in patients with aura has been firstly attribu-
ted to the occurrence of repeated oligoemia, that may
lead to a local hypoperfusion and to minor brain injury
[4], and, more recently, to changes in the permeability of
the blood– brain barrier by activation of matrix metallo-
proteinases (MMPs), a family of neutral metallopro-
teases, due to the oxygen free radicals, nitric oxide and
proteases highly released during the spreading depres-
sion, a self-propagating wave of neuronal and glial
depolarization which generates a transient loss of mem-
brane ionic gradients [66].
This hypothesis, however, does not explain the devel-
opment of such lesions in patients with migraine with-
out aura, who present them similarly to migraineurs
with aura, although to a lesser degree [65]. In MO
patients, a higher attack frequency and longer disease
duration have been called upon to explain the develop-
ment of WMHs [4,65,67,68]. These data are concordant
with our recent findings, which demonstrated a similar
prevalence of WMHs both in migraine without aura and
tension-type headache, and suggested a major link be-
tween the frequency (rather than the intensity) of crises
and MRI positivity [69], and with those of Kurth et al.,
which associated any history of severe headache with the
increasing volume of white matter hyperintensities [70].
The above-mentioned effects of risk factors, comorbidity
and other mechanisms (e.g. endothelial dysfunction,
assumption of triptans with vasoconstrictor activity) may
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[17-26,68].
The recent finding that these injuries, like those of
headache-free patients, may progress over time raises
some doubts about their benign nature: among 26
subjects with WMHs, 8 patients had indeed new lesions
after a follow-up of a mean duration of 33.2 months
[71]. However, in contrast to previously published data
[72], there is at the moment no evidence that migraine,
other primary headaches or migraine-related medication
use are risk factors for cognitive dysfunction or cognitive
deterioration over time [70,73]. Furthermore, Serafini
et al. found that patients with PWMHs reported fewer
depressive symptoms than patients without PWMHs,
and those with WMH lesions reported less severity of
their depression state [74].
Conclusions: implications in clinical practice
The growing evidence of a greater risk of ischemic
stroke in patients with migraine, particularly in the case
of aura, female sex, smoking habits, age < 45 years and a
history of oral contraceptive assumption [11,14], the
recent finding of a cerebral protective effect of aspirin
(in terms of a reduction of the risk of ischaemic stroke,
in the dose of 100 mg on alternate days) [15], and of the
risk, although already debated [6,11-13], of myocardial
infarction in migraine with aura, raise some doubts
about the complete benignity of migraine [75]. A mi-
graineur subject, even with a low absolute CV risk
(female, age under 45 years) may, in fact, be at a higher
relative risk due to the presence of other factors, such as
aura component, smoking and the use of oral contracep-
tives. It is therefore important to act on these factors in
order to reduce the vascular hazard. In addition, because
the higher headache frequency and long-term migraine
may result in a worse cardiometabolic profile, in terms
of a higher Framingham risk score [26], greater risk of
development of atherosclerosis [45], insulin resistance
[30,33] and metabolic syndrome [33], it may be useful to
reduce the number and severity of attacks. This is not
only to alleviate the painful symptoms, but also to im-
prove the prognosis in these patients, also considering
that a higher frequency of attacks may be related to a
history of chronic intake of non-steroidal anti-inflamma-
tory drugs (NSAIDs) and triptans, both well known to
be associated with a greater likelihood of developing car-
diovascular events. At present, however, there is a lack
of evidence that the presence of white matter hyperin-
tensities, although possibly correlating positively with a
higher attack frequency and duration of the disease
[69,70], can deteriorate the cognitive function and
worsen -per se- the risk of cardiovascular events in mi-
graine patients [70,73]. If it proves true that they are
indicative of CV risk in migraine, these WMHs, byrevealing the presence of subclinical organ damage,
could be a useful marker in migraineurs to evaluate the
increased hazard for CV events as well as the presence
of carotid intima-media thickening and atherosclerosis
in the general population. New longitudinal studies are
needed to draw definite conclusions in the future.
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